Cyclin-dependent kinase 1 (CDK1)

Overview

Cyclin dependent kinase 1 (CDK1) is a core serine/threonine protein kinase that plays a central role in cell-cycle control, particularly the transition into and progression through mitosis. In normal biology, CDK1 functions as part of the cyclin-dependent kinase network that coordinates DNA replication, checkpoint control, and cell division. Its activity is tightly regulated by cyclins and by inhibitory phosphorylation events, reflecting its importance as a gatekeeper of proliferative progression.

In biomedical research, CDK1 is widely studied as an anticancer target because many tumors depend on dysregulated cell-cycle machinery for continued growth. Recent studies have also linked CDK1 to DNA damage responses and signaling pathways beyond canonical mitotic control, including cGAS-STING-related immune activation and checkpoint kinase regulation. These findings place CDK1 at the intersection of cell-cycle biology, genome stability, and therapeutic vulnerability in Cancers such as nasopharyngeal carcinoma, hepatocellular carcinoma, lymphoma, and other invasive malignancies.

Recent Publications Summary

Recent studies continued to position Cyclin-dependent kinase 1 (CDK1) as a central cell-cycle regulator and therapeutic target across cancer and non-cancer contexts. In glioblastoma, trichodermin induced G2/M arrest with p53 activation and downregulation of cyclin B, cyclin A, and CDK1, while also promoting caspase-dependent apoptosis and suppressing invasion; the compound further showed synergy with temozolomide in vitro and inhibited intracranial tumor growth in an orthotopic mouse model 42474259Jul. In colorectal cancer, a network-based study integrating WGCNA, machine learning, qRT-PCR, Western blotting, and functional assays identified CDK1 as a key regulator linked to malignant progression, with the abstract indicating that its relationship with a transcription factor was being investigated 42470494Jul. Pan-cancer analyses of breast, ovarian, and colorectal Cancers likewise highlighted CDK1 as a hub target alongside AURKA and CCNB1, supporting its recurrent appearance in shared oncogenic programs 42224282Jun.

Several publications focused on CDK1-directed drug discovery and structural optimization. A computational study of pyrazolopyrimidine inhibitors used docking, 3D-QSAR, and molecular dynamics to define features associated with CDK1 inhibition and identified compounds with strong predicted binding and stable interactions in the CDK1 active site 42329991Jun. A separate medicinal chemistry campaign designed selective CDK1 inhibitors based on 1,2,4-triazolobenzene sulfonamides; lead compound 11l showed nanomolar CDK1 potency, selectivity over CDK2, Aurora A, and CDK4, and induced G2/M arrest with downregulation of CDK1 and cyclin B1, together with replication stress and p53 pathway activation 41903286Mar. Another study on selective CDK2 inhibitor design explicitly used CDK1 as the counter-target, reporting a compound with good selectivity versus CDK1 and in vivo antitumor activity in a CDK2 xenograft model 42328801Jun.

CDK1 was also implicated in tumor microenvironment modulation and combination strategies. In pancreatic cancer, an in vivo CRISPR-Cas9 screen identified the CDK1/Cyclin B1 complex as a tumor-intrinsic driver of immune evasion; genetic or pharmacologic inhibition of this complex promoted a T cell-inflamed tumor microenvironment and synergized with PD-1 blockade, with mechanistic links to reduced Rb phosphorylation, restored NF-κB activity, increased GM-CSF (Csf2), and enhanced dendritic-cell recruitment 41921857Apr. In nasopharyngeal carcinoma, a ROS-sensitive nanoparticle co-delivering cisplatin prodrug and the CDK1 inhibitor RO-3306 was designed to block CDK1-driven DNA repair and CDK1-mediated cGAS phosphorylation, thereby amplifying DNA damage, activating cGAS-STING signaling, and improving chemo-immunotherapy responses in mouse models 41966338Apr. In vascular disease, elafibranor reduced neointima formation in a carotid artery injury model by downregulating CDK1 expression and inducing G2/M arrest in vascular smooth muscle cells 42150712May.

Beyond oncology, CDK1 emerged in phosphoproteomic analyses of gestational polypropylene nanoplastic exposure, where it was predicted as the top upstream kinase in a cellular senescence-associated network; although CDK1 abundance increased, its canonical cell-cycle-driving function appeared altered in the context of placental aging 42430922Jul. In hepatocellular carcinoma, integrative network toxicology and multi-omics analyses identified CDK1 among six hub genes upregulated in tumors and predicted stable binding of bisphenol A to CDK1 in docking and dynamics simulations 42118483May. Together, these publications reinforce CDK1 as a recurrent node in cell-cycle control, DNA damage responses, invasion, immune evasion, and cellular senescence-associated remodeling across diverse disease settings.

What Changes, What Holds

1. CDK1 remains a recurrent cancer-node, but the new work mainly sharpens its breadth rather than changing its core role
REINFORCES The glioblastoma and pan-cancer findings fit the established view of CDK1 as a mitotic driver and anticancer target, while the colorectal study adds another malignancy-specific association without overturning mechanism. The practical implication is that CDK1 continues to look like a shared vulnerability across tumors, but these are still largely preclinical and correlative signals that need causal validation before they can refine patient selection or treatment strategy 42474259Jul42224282Jun.

2. Selectivity and structure-guided inhibition of CDK1 are becoming more precise, but the therapeutic concept is unchanged
REINFORCES These studies strengthen the drug-discovery case by showing that CDK1 can be inhibited with nanomolar potency and improved selectivity, and by defining structural features that support that goal. They do not alter the baseline understanding that CDK1 is a drug target; instead, they make the target more tractable. The CDK2-countertarget work also underscores how closely related kinase selectivity remains a central design problem rather than a new biological role for CDK1 42329991Jun41903286Mar.

3. CDK1 inhibition is increasingly being used to reprogram immunity and DNA repair, extending its therapeutic relevance beyond simple cell-cycle blockade
NEW DIRECTION The pancreatic and nasopharyngeal carcinoma studies go beyond the baseline’s mitotic-control framing by linking CDK1/Cyclin B1 to immune evasion, cGAS-STING activation, and response to PD-1 blockade or chemo-immunotherapy. That does not contradict CDK1’s cell-cycle role, but it adds a new functional layer: CDK1 can shape the tumor microenvironment and DNA-damage signaling. These are preclinical findings, so the mechanistic hierarchy still needs confirmation in vivo and across tumor types 41921857Apr41966338Apr.

4. CDK1 is now being implicated in non-oncologic remodeling states, but these are extensions of its stress-response biology rather than reversals of the baseline
NEW DIRECTION The vascular injury and placental senescence analyses place CDK1 in contexts the Overview does not cover, namely neointima formation and nanoplastic-associated placental aging. That broadens the entity’s relevance from cancer and checkpoint control to tissue remodeling and senescence-associated networks. The hepatocellular carcinoma toxicology work similarly reinforces CDK1 as a hub under chemical perturbation. None of this displaces the established cell-cycle account; it suggests CDK1 may be a common readout and mediator of pathological remodeling across organs 42150712May42430922Jul42118483May.

Overview update candidates: CDK1’s role in tumor immune evasion and cGAS-STING-linked chemo-immunotherapy; CDK1 involvement in non-oncologic remodeling/senescence contexts.